Brief: Incannex Healthcare Completes Dosing In Phase 1 Clinical Trial To Assess Multi-Use, Anti-Inflammatory Drug Ihl-675A Proceeds To Phase 2 Clinical Trials
13/10/2022 13:10
Oct 13 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX COMPLETES DOSING IN PHASE 1 CLINICAL TRIAL TO
ASSESS
MULTI-USE, ANTI-INFLAMMATORY DRUG IHL-675A; PROCEEDS TO PHASE 2
CLINICAL TRIALS
* INCANNEX HEALTHCARE LTD- IHL-675A HAS BEEN WELL TOLERATED,
WITH
NO ADVERSE EVENTS OF CONCERN REPORTED TO DATE
Source text for Eikon: ID:nGNX89y7rT
Further company coverage: IHL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed